🇺🇸 Spironolactone 50 mg in United States

30 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 5 reports (16.67%)
  2. Dizziness — 4 reports (13.33%)
  3. Dyspnoea — 3 reports (10%)
  4. Headache — 3 reports (10%)
  5. Malaise — 3 reports (10%)
  6. Nausea — 3 reports (10%)
  7. Palpitations — 3 reports (10%)
  8. Condition Aggravated — 2 reports (6.67%)
  9. Confusional State — 2 reports (6.67%)
  10. Dyspepsia — 2 reports (6.67%)

Source database →

Spironolactone 50 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Spironolactone 50 mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Spironolactone 50 mg in United States?

Wake Forest University Health Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.